New note provides greater repayment flexibility and less dilution with elimination of mandatory amortization payments, increased conversion floor price to $0.35, and expanded mandatory ELOC payments from 33% to 50% BERKELEY, Calif, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces th

– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda’s externalized assets portfolio – EMERYVILLE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has amended its collaboration, originally established in 2006, with Taked

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effectInflaRx anticipates meeting with the FDA to determine a potential development path forward in PG, which the Company anticipates would only be conducted in co

Chicago’s healthcare industry fully combines economic scale with clinical excellence and innovation. Making it one of the most influential healthcare markets in the country” — Strahil Ovcharov, the VP of Sales & Marketing at Blacksmith. CHICAGO, IL, UNITED STATES, December 30, 2025 / EINPresswire.com / -- Blacksmith, a trusted web design partner in Chicago , explains some key stats and trends for the Chicago healthcare industry. These stats and trends can help healthcare companies adapt their st

Collaborative Partnership to Enhance Continuum of Coordinated Comprehensive Community-Based Cancer Care Joining forces with HopeHealth supports and complements the mission for Precision Radiation Oncology Rhode Island to deliver compassionate, patient-centered cancer care.” — Greg Mercurio, Jr, CEO Precision Radiation Oncology Rhode Island PROVIDENCE, RI, UNITED STATES, December 30, 2025 / EINPresswire.com / -- Precision Radiation Oncology Rhode Island (PRORI), a leading provider of advanced rad

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. “Jack” Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive,

Biotech executives and shareholders can breathe easier heading into the new year for the first time in nearly half a decade. The industry’s leaders will arrive at January’s JP Morgan Healthcare Conference riding a surge in M&A activity and the XBI in recovery from a years-long slide. While that exchange-traded fund remains below its pandemic-fueled peak in 2021, it’s above $120 and is up more than 80% from April. That warm glow had been missing since the pandemic sugar high faded and set off a r

New Delhi: Statins , which help treat high cholesterol, may significantly reduce risk of death and major cardiovascular events in adults with type 2 diabetes , including among those considered at low cardiovascular risk , according to a study. The findings published in the journal Annals of Internal Medicine challenge a long-standing uncertainty about whether patients at the lowest risk benefit from preventive statin therapy, and suggest that the drugs may have a broader protective value than pr

Las Vegas-based New Horizon Medical Solutions announced it has acquired Applied Tissue Technologies' transparent negative-pressure wound therapy device and micrografting kit, expanding its portfolio of wound care offerings. New Horizon offers biologics and advanced wound care tools, including skin substitutes developed using amniotic membrane technology. The company also offers workflow and staff training tools, as well as technology integration services, aimed at reducing administrative burden,

Insilico Medicine, one of the original AI-driven drug discoverers, has stuck the landing after four years of trying to go public. The 11-year-old drug developer on Tuesday raised gross proceeds of approximately $293 million via its listing on the Hong Kong Stock Exchange. Insilico’s share price escalated 24% in its first trading session, ending the debut day with a market capitalization of about $2.15 billion (16.71 billion Hong Kong dollars). The biotech’s float was one of the largest Hong Kong